Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9128815 | PMC |
| http://dx.doi.org/10.1093/ajhp/zxac030 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
FGFR-Altered Urothelial Carcinoma: Resistance Mechanisms and Therapeutic Strategies.
Target Oncol
January 2025
Hoag Family Cancer Institute, 1 Hoag Drive, Building 41, Newport Beach, CA, 92663, USA.
Fibroblast growth factor receptor (FGFR) 2/3 alterations have been implicated in tumorigenesis in several malignancies, including urothelial carcinoma. Several FGFR inhibitors have been studied or are in development, and erdafitinib is the sole inhibitor to achieve regulatory approval. Given the rapidly evolving treatment landscape for advanced urothelial carcinoma, including regulatory approvals and withdrawals, determining the most appropriate treatment strategies and sequencing for FGFR-altered urothelial carcinoma is becoming increasing critical.
View Article and Find Full Text PDFExpert Consensus on the Diagnosis and Treatment of FGFR Gene-Altered Solid Tumors.
Glob Med Genet
December 2024
Department of Respiratory Medicine, Affiliated Jinling Hospital, Medical School of Nanjing University, Nanjing, Jiangsu, People's Republic of China.
Article Synopsis
- FGFR is a vital receptor involved in growth and tissue repair, but its gene mutations can lead to cancer by disrupting essential processes.
- Small molecule drugs and antibodies targeting FGFR mutations, like erdafitinib and pemigatinib, have shown clinical efficacy in treating certain cancer types.
- Effective screening methods for FGFR variants are essential for utilizing FGFR inhibitors in treatment, and a consensus has been developed to standardize diagnosis and treatment processes.
Real-World Large Sample Assessment of Drug-related Dry Eye Risk: Based on the FDA Adverse Event Reporting System Database.
Asia Pac J Ophthalmol (Phila)
October 2024
Xiamen University affiliated Xiamen Eye Center, Fujian Provincial Key Laboratory of Ophthalmology and Visual Science, Fujian Engineering and Research Center of Eye Regenerative Medicine, Eye Institute of Xiamen University, School of Medicine, Xiamen University, Xiamen, Fujian 361005, China; Department of Ophthalmology, the First Affiliated Hospital of University of South China, Hengyang, Hunan 421001, China; Department of Ophthalmology, Xiang'an Hospital of Xiamen University, Xiamen, Fujian 361005, China. Electronic address:
Purpose And Design: This study aimed to evaluate the risk of drug-related dry eye using real-world data, underscoring the significance of tracing pharmacological etiology for distinct clinical types of dry eye.
Methods: Analyzing adverse event reports in the Food and Drug Administration Adverse Event Reporting System (FAERS) from January 2004 to September 2023, we employed disproportionality analysis and the Bayesian confidence propagation neural network algorithm. The analysis involved categorizing drugs causing dry eye, assessing risk levels, and conducting segmental assessments based on the time of onset of drug-related dry eye adverse reactions.
Matching-Adjusted Indirect Comparison of the Efficacy and Safety of Erdafitinib vs Enfortumab Vedotin in Patients with Locally Advanced Metastatic Urothelial Carcinoma.
J Health Econ Outcomes Res
August 2024
Cytel Inc., Toronto, Ontario, Canada.
For patients with locally advanced or metastatic urothelial carcinoma (la/mUC), prognosis is poor and effective treatment options are limited. Erdafitinib is an oral fibroblast growth factor receptor (FGFR) kinase inhibitor approved by the FDA for the treatment of adults with la/mUC harboring FGFR alterations whose disease progressed following at least 1 prior line of therapy, including a PD-1 or PD-L(1) inhibitor, based on the phase 3, randomized THOR trial (NCT03390504, Cohort 1). To compare the efficacy and safety of erdafitinib vs enfortumab vedotin-ejfv (EV) in the absence of head-to-head comparison via an anchored matching-adjusted indirect comparison (MAIC).
View Article and Find Full Text PDFTissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.
Eur Urol
January 2025
Department of Urology, San Raffaele Hospital and Scientific Institute, Milan, Italy.
The European Association of Urology (EAU), National Comprehensive Cancer Network, and European Society for Medical Oncology guidelines recommend PD-L1 and FGFR testing for patients with locally advanced bladder cancer or upper tract urothelial cancer (UTUC) according to specific eligibility criteria; positive results indicate therapy with immune checkpoint inhibitors or erdafitinib, respectively. The EAU guidelines recommend PD-L1 testing for subsequent adjuvant therapy in high-risk UC, and germline DNA sequencing in patients with UTUC positive for DNA mismatch repair alterations.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!